In summary, high expression of EIF4A3 may contribute to tumor progression by remodeling the immune microenvironment in BLCA patients; however, owing to its association with PD-L1 expression, it may serve as a predictor for immunotherapy response. This evidence concerns the gene EIF4A3 and bladder transitional cell carcinoma.